T细胞恶性肿瘤的新型靶向疗法
Novel Targeted Therapies for T-Cell Malignancies.
作者信息
Tesio Melania
机构信息
UR LIB "Lymphoma Immune Biology"-INSERM U111, Centre International de Recherche en Infectiologie (CIRI), 69007 Lyon, France.
出版信息
Cancers (Basel). 2022 Aug 16;14(16):3955. doi: 10.3390/cancers14163955.
Abstract
T-cell malignancies comprise a heterogeneous group of cancers resulting from the clonal expansion of T-cells at different developmental stages [...].
摘要
T细胞恶性肿瘤是一组异质性癌症，由不同发育阶段的T细胞克隆性扩增引起[...]。
相似文献
1
Novel Targeted Therapies for T-Cell Malignancies.
Cancers (Basel). 2022 Aug 16;14(16):3955. doi: 10.3390/cancers14163955.
2
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. doi: 10.1073/pnas.1611421113. Epub 2016 Oct 3.
3
The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.
Adv Exp Med Biol. 2018;1068:119-133. doi: 10.1007/978-981-13-0502-3_10.
4
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Best Pract Res Clin Haematol. 2019 Dec;32(4):101097. doi: 10.1016/j.beha.2019.101097. Epub 2019 Oct 18.
5
Detection of clonally rearranged T-cell-receptor gamma chain genes from T-cell malignancies and acute inflammatory rheumatic disease using PCR amplification, PAGE, and automated analysis.
Ann Hematol. 1997 Mar;74(3):123-30. doi: 10.1007/s002770050269.
6
[Leukemia stem cell and clonal evolution].
Nihon Rinsho. 2014 Jun;72(6):1012-7.
7
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer.
Immunooncol Technol. 2019 Oct 9;3:1-7. doi: 10.1016/j.iotech.2019.09.003. eCollection 2019 Oct.
8
Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases.
Front Med. 2015 Dec;9(4):468-77. doi: 10.1007/s11684-015-0419-6. Epub 2015 Nov 11.
9
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.
10
Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.
Blood. 2001 Jan 15;97(2):523-7. doi: 10.1182/blood.v97.2.523.
本文引用的文献
1
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.
2
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29.
3
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Blood. 2021 Jul 1;137(26):3595-3603. doi: 10.1182/blood.2020009806.
4
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303.
5
Novel targeted therapies of T cell lymphomas.
J Hematol Oncol. 2020 Dec 31;13(1):176. doi: 10.1186/s13045-020-01006-w.
6
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.
J Invest Dermatol. 2021 Mar;141(3):484-495. doi: 10.1016/j.jid.2020.07.026. Epub 2020 Nov 5.
7
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
Blood Adv. 2020 Oct 13;4(19):4640-4647. doi: 10.1182/bloodadvances.2020002396.
8
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
Pediatr Blood Cancer. 2020 Dec;67(12):e28688. doi: 10.1002/pbc.28688. Epub 2020 Sep 8.
9
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Cancers (Basel). 2020 Aug 15;12(8):2293. doi: 10.3390/cancers12082293.
10
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.
Curr Treat Options Oncol. 2020 May 28;21(7):57. doi: 10.1007/s11864-020-00757-5.
Zotero 插件